Egetis Therapeutics

Mendus

Medivir

Genovis

Bioinvent International

Saniona

Karolinska Development

Q-linea

- ASTar is still experiencing long sales cycles in the European market
- ASTar is still not proven on the crucial US market 
- Q-linea has not established a new commercial partner after Thermo Fisher.

- ASTar is approved and clinically proven both in the US and in Europe
- ASTar is a fully developed system
- Q-linea is validated both clinically, regulatory and commercially following the earlier partnership with Therma Fisher.

- Q-linea is still far from break-even sales 
- Q-linea has limited access to growth capital and the current rights issue is very important. 
- Sales cycles are long, especially in Europe.

- ASTar is a fully developed system
- ASTAr is addressing a very large global market
- THe US market is likely to be significantly more dynamic and receptive compared with the European market.

- Q-linea has a substantial OPEX base, and the company is still far from break-even 
- Earlier sales target has not been achieved
- The senior management team has a limited shareholding

- Q-linea is transparent and the company has a strong leading owner in Nexttobe
- ASTar is a fully developed solution
- ASTar is addressing the more significant part of the market based on medium and larger hospitals and labs.